HLS Therapeutics Inc (HLS) - Total Liabilities
Based on the latest financial reports, HLS Therapeutics Inc (HLS) has total liabilities worth CA$75.72 Million CAD (≈ $54.78 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HLS Therapeutics Inc - Total Liabilities Trend (1996–2025)
This chart illustrates how HLS Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See HLS current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
HLS Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of HLS Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LOT VACUUM Co. Ltd
KQ:083310
|
Korea | ₩78.67 Billion |
|
Prevas AB
ST:PREV-B
|
Sweden | Skr666.84 Million |
|
Kura Sushi Asia Co Ltd
TWO:2754
|
Taiwan | NT$3.29 Billion |
|
Champion Building Materials Co Ltd
TW:1806
|
Taiwan | NT$2.91 Billion |
|
Studentbostader I Sverige AB
ST:STUDBO
|
Sweden | Skr5.90 Billion |
|
Raba Jarmuipari Holding Nyrt
BUD:RABA
|
Hungary | Ft32.21 Billion |
|
Topower Co Ltd
TWO:3226
|
Taiwan | NT$598.33 Million |
|
Axis Corporation
TWO:6292
|
Taiwan | NT$551.14 Million |
Liability Composition Analysis (1996–2025)
This chart breaks down HLS Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HLS Therapeutics Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HLS Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HLS Therapeutics Inc (1996–2025)
The table below shows the annual total liabilities of HLS Therapeutics Inc from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$75.72 Million ≈ $54.78 Million |
-14.50% |
| 2024-12-31 | CA$88.56 Million ≈ $64.07 Million |
-20.47% |
| 2023-12-31 | CA$111.36 Million ≈ $80.56 Million |
-4.27% |
| 2022-12-31 | CA$116.33 Million ≈ $84.15 Million |
+1.01% |
| 2021-12-31 | CA$115.17 Million ≈ $83.31 Million |
-14.47% |
| 2020-12-31 | CA$134.66 Million ≈ $97.41 Million |
-4.82% |
| 2019-12-31 | CA$141.47 Million ≈ $102.34 Million |
-4.37% |
| 2018-12-31 | CA$147.94 Million ≈ $107.01 Million |
-27.58% |
| 2017-12-31 | CA$204.26 Million ≈ $147.76 Million |
+36901.53% |
| 2016-12-31 | CA$552.04K ≈ $399.34K |
-3.52% |
| 2015-12-31 | CA$572.17K ≈ $413.90K |
-95.74% |
| 2014-12-31 | CA$13.42 Million ≈ $9.71 Million |
-6.10% |
| 2013-12-31 | CA$14.29 Million ≈ $10.34 Million |
+64.46% |
| 2012-12-31 | CA$8.69 Million ≈ $6.28 Million |
-35.40% |
| 2011-12-31 | CA$13.45 Million ≈ $9.73 Million |
+10.51% |
| 2010-12-31 | CA$12.17 Million ≈ $8.80 Million |
-30.62% |
| 2009-12-31 | CA$17.54 Million ≈ $12.69 Million |
+0.07% |
| 2008-12-31 | CA$17.53 Million ≈ $12.68 Million |
-37.18% |
| 2007-12-31 | CA$27.90 Million ≈ $20.18 Million |
+50.64% |
| 2006-12-31 | CA$18.52 Million ≈ $13.40 Million |
+30.65% |
| 2005-12-31 | CA$14.18 Million ≈ $10.25 Million |
+22.65% |
| 2004-12-31 | CA$11.56 Million ≈ $8.36 Million |
-22.00% |
| 2003-12-31 | CA$14.82 Million ≈ $10.72 Million |
+255.47% |
| 2002-12-31 | CA$4.17 Million ≈ $3.02 Million |
-29.57% |
| 2001-12-31 | CA$5.92 Million ≈ $4.28 Million |
-54.82% |
| 2000-12-31 | CA$13.10 Million ≈ $9.48 Million |
-43.87% |
| 1999-12-31 | CA$23.34 Million ≈ $16.88 Million |
+31.05% |
| 1998-12-31 | CA$17.81 Million ≈ $12.88 Million |
-25.92% |
| 1997-12-31 | CA$24.04 Million ≈ $17.39 Million |
+138.23% |
| 1996-12-31 | CA$10.09 Million ≈ $7.30 Million |
-- |
About HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances … Read more